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Abstract
Somatostatin limits cell growth by inhibiting the proliferative
activity of growth factor receptors. In this study, it is shown that
in pituitary tumor cells, the somatostatin analogue octreotide
produces its antiproliferative action by inducing the expression
the tumor suppressor gene Zac1 . ZAC/Zac1 induces cell cycle
arrest and apoptosis and is highly expressed in normal
pituitary, mammary, and ovarian glands but is down-regulated
in pituitary, breast, and ovarian tumors. Knocking down Zac1
by RNA interference abolished the antiproliferative effect of
octreotide in pituitary tumor cells, indicating that Zac1 is
necessary for the action of octreotide. The effect of octreotide
on Zac1 expression was pertussis toxin sensitive and was
abolished after transfection with a dominant negative vector
for SHP-1. Zac1 is a target of the phosphatidylinositol 3-kinase
(PI3K) survival pathway. Octreotide treatment decreased
the tyrosine phosphorylation levels of the PI3K regulatory
subunit p85, induced dephosphorylation of phosphoinositide-
dependent kinase 1 (PDK1) and Akt, and activated glycogen
synthase kinase 3B (GSKB). Therefore, in pituitary tumor cells,
somatostatin analogues produce their antiproliferative action
by acting on the PI3K/Akt signaling pathway and increasing
Zac1 gene expression. (Cancer Res 2006; 66(3): 1576-82)
Introduction
Somatostatin regulates neurotransmission, inhibition of hormone
secretion, and proliferation, and is used for the treatment of
neuroendocrine tumors. Somatostatin binds to a family of receptors
(SSTR1-5), which belong to the seven-transmembrane-domain
G-protein coupled receptors (GPCR; ref. 1), and exerts its
antiproliferative action by inducing G0-G1 cell cycle arrest (2) or
G2-M arrest and apoptosis (3).
Somatostatin binding to SSTR, receptor heterodimerization, G
protein sequestration, and the intracellular effectors of SSTR
signaling were extensively studied (reviewed in refs. 1, 4–7).
Somatostatin limits cell growth by inhibiting the proliferative
activity of growth factor receptors. Phosphotyrosine phosphatases
(PTP) play a central role in this process by dephosphorylating
epidermal growth factor (EGF) receptor (8). Indeed, PTP activity
was found to be increased after somatostatin treatment in many cell
systems (9–11) and was pertussis toxin sensitive, indicating the
involvement of Gia (8, 12). SHP-1/PTP1C, which belongs to the
cytosolic PTP family and contains Src homology 2 domains, was
reported to be recruited to the plasma membrane after somato-
statin stimulation (13, 14) and to associate with and mediate the
antiproliferative effect of SSTR2 (15–17). Another PTP, SHP-2/
PTP1D, was found to mediate the antiproliferative action of SSTR1
in Chinese hamster ovary (CHO)-SSTR1 cells (18) and of SSTR2,
SSTR3, and SSTR4 in NIH 3T3 cells stably transfected with each
SSTR (19). In CHO cells stably transfected with SSTRs, somatostatin
was shown to act through the mitogen-activated protein kinase
(MAPK) pathway (20, 21). Other studies have also shown that
somatostatin can activate the phosphatidylinositol 3-kinase (PI3K)
pathway (20, 22).
However, there is little information about the transcription factors
and gene targets mediating the antiproliferative action of somato-
statin. Somatostatin stops cell cycle progression by inducing the
cyclin-dependent kinase inhibitor p27/Kip1 (17, 23). On the other
hand, cells like the rat mammosomatotrophinoma cell line GH3
do not express p27/Kip1 (24) but they nevertheless respond to
somatostatin analogue treatment by decreasing cell proliferation,
indicating that other genes can mediate the antiproliferative action
of somatostatin.
Searching for candidate gene targets, we focused on the
putative tumor suppressor gene ZAC/Zac1. In a previous study,
ZAC was shown to be highly expressed in the normal anterior
pituitary gland but down-regulated in most pituitary adenomas
(25). An interesting observation was that acromegaly-associated
pituitary adenomas had high ZAC levels, sometimes comparable
to the ones found in the normal human anterior pituitaries.
Because these tumors derive from patients previously treated
with somatostatin analogues, it is possible that their high ZAC
expression is due to the somatostatin treatment. The aim of the
present study was to investigate whether ZAC/Zac1 mediates the
antiproliferative action of octreotide on GH3 cells and to elucidate
the signaling events triggered by octreotide treatment in pituitary
tumor cells.
Materials and Methods
Reagents. Cell culture materials were purchased from Life Technol-
ogies (Karlsruhe, Germany), Nunc (Wiesbaden, Germany), and Sigma
(St. Louis, MO). Octreotide was provided by the American Peptide
Company (Sunnyvale, CA); pertussis toxin, orthovanadate, and PD098059
were from Sigma; and LY294002, wortmannin, SB-415286, and lithium
chloride were from Calbiochem (Bad Soden, Germany). Octreotide was
dissolved in 0.01 mol/L acetic acid and LY294002, wortmannin, and
SB-415286 were dissolved in DMSO.
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Cell culture. GH3 cells (American Type Culture Collection, Manassas,
VA) were cultured in DMEM supplemented with 10% FCS, 2.2 g/L
NaHCO3, 10 mmol/L HEPES, 2 nmol/L glutamine, 2.5 mg/L amphotericin
B, and 105 units/L penicillin-streptomycin at 37jC and 5% CO2. Cells
(4  105) were treated with octreotide, pertussis toxin, orthovanadate,
LY294002, wortmannin SB-415286, and lithium alone or in the combina-
tion appropriate for each experiment, dissolved in serum-free DMEM. The
carriers in which the substances were dissolved were used as controls.
Pertussis toxin was administered 12 hours, orthovanadate 2 hours, and
lithium 1 hour before octreotide treatment. Treatment time was 20 hours
unless otherwise indicated.
RNA extraction and semiquantitative reverse transcription-PCR.
RNA was extracted by the guanidinium-isothiocyanate-phenol method. PCR
for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was done on 1 Ag
RNA to exclude genomic DNA contamination. One microgram of RNA was
reverse transcribed using random hexanucleotides and semiquantitative
radioactive PCR was done for Zac1 and GAPDH (internal control) under
restrictive conditions as previously described (25). Each reverse transcrip-
tion-PCR (RT-PCR) was done in RNA extracted from three independent
experiments.
Western blot analysis. Cells were treated as described for 1, 3, and 6
hours. Cell lysates were separated by PAGE and blotted using standard
procedures (26). Primary antibodies were against SHP-1/PTP1C, SHP-2/
PTP1D (both made in mouse; Transduction Laboratories, Lexington, KY),
Akt, phosphoinositide-dependent kinase 1 (PDK1), glycogen synthase kinase
3h (GSK3h), p70/S6K, FKHR, phosphorylated Akt (Ser473), Akt (Thr308),
PDK1 (Ser241), GSK-3h (Ser9), phosphatase and tensin homologue (PTEN;
Ser380), p70/S6K (Ser371), and FKHR (Ser256; all made in rabbit; New England
Biolabs GmbH, Frankfurt am Main, Germany). Horseradish peroxidase–
conjugated secondary antibodies were used against mouse and rabbit
(Amersham Pharmacia Biotech, Freiburg, Germany). Each Western blot
was done in lysates obtained from three independent experiments.
Coimmunoprecipitation. GH3 cells were treated with 1 Amol/L
octreotide for 10, 30, and 60 minutes and collected in ice-cold lysis buffer
[150 mmol/L NaCl, 50 mmol/L HEPES (pH 7.4), 1 mmol/L sodium
orthovanadate, 2 mmol/L EDTA, 2 mmol/L phenylmethylsulfonyl fluoride,
and 1% NP40]. Protein (600 Ag) was immunoprecipitated with an antibody
against the p85 subunit (Upstate, Charlottesville, VA) or with a control
mouse immunoglobulin G (IgG). Protein A Sepharose (Amersham
Pharmacia Biotech) was used as previously described (26). The immuno-
precipitates were extensively washed and protein bound to sepharose was
eluted and separated by 10% SDS-PAGE (27). Western blot was done using
the horseradish peroxidase–conjugated anti-phosphotyrosine 4G10
(Upstate), anti-p85, or anti-SHP-1 monoclonal antibody. Coimmunopreci-
pitation was done in two independent experiments and was repeated using
Protein G Sepharose.
Plasmids. SHP-1/C453S (SHP-1dn; ref. 17) and C/S SHP-2 (SHP-2dn;
ref. 19) dominant negative mutants and the Ghg sequester h-ARK-CT (gift
of P. Voigt, Institute of Pharmacology, Charité-Medical University, Campus
Benjamin Franklin, Berlin, Germany) were used. The p53-Luc construct
(Mercury pathway profiling system, Clontech Laboratories, Inc., Palo Alto,
CA) has the p53 responsive element upstream to the TATA box of the
herpes simplex virus thymidine kinase promoter and the reporter gene
luciferase.
Transfection and reporter assays. Cell transfection was done with
SuperFect (Qiagen GmbH, Hilden, Germany). Cells (3  105) were
transfected for 3 hours with 1 Ag of SHP-1dn, SHP-2dn, or h-ARK-CT
plasmid, left in cell growth medium overnight, and treated for 20 hours
with 1 Amol/L octreotide. RNA was extracted and semiquantitative RT-
PCR was done for Zac1. Lysates of cells transfected with h-ARK-CT were
analyzed for phosphorylated Akt by Western blot and lysates of cells
transfected with SHP-1dn were immunoprecipitated with p85 as
described above. Each transfection experiment was done in duplicate.
To confirm the SHP-1 and 2dn incorporation, Western blot was done for
hemagglutinin (Acris, Hiddenhausen, Germany) and c-myc (Santa Cruz
Biotechnology, Santa Cruz, CA), respectively. Incorporation of h-ARK-CT
was shown by determination of Ca2+ oscillations in transfected cells
before and after treatment with the muscarinic agonist carbachol (Sigma)
as previously described (28).
Cells transfected with p53-Luc were treated with octreotide for 6 hours
and luciferase activity was measured by a Berthold luminometer. The
pEGFP-C2 vector (Clontech) encoding an optimized variant of the green
fluorescent protein (GFP) was used as control of the transfection efficiency.
Data are expressed as the ratio of p53 relative luciferase activity to GFP
absorbance. Each experiment was done in triplicate.
RNA interference. Double-stranded small interfering RNA (siRNA), with
19-nucleotide (nt) duplex RNA and 2-nt 3VdTdT overhangs, was synthesized
by MWG Biotech (Ebersberg, Germany) in deprotected and desalted form
using the 2V-ACE technology. The 19-nt pair was 5V-AAGUGCUCCAAGACU-
GAGUGU, which was designed according to the guidelines described in
ref. 29. The sequence was confirmed to be unique for the rat Lot1 using the
BLAST search algorithm of the National Center for Biotechnology
Information. One scrambled siRNA (Scramble II, MWG Biotech) was used
as a control. Similarly, a siRNA was designed against p53 (5V-ACGUGCU-
CACACUGGCUAATT).
GH3 cells were transfected with 100 nmol/L ‘‘scramble’’ and with 25,
50, and 100 nmol/L siRNA against Zac1 using SuperFect (Qiagen) for 3
hours, and then were left in cell growth medium overnight to recover. The
day after, they were split and distributed for proliferation or cyclic AMP
(cAMP) assays whereas a part was kept for RNA extraction. Cells for RNA
extraction were harvested at the same time as the proliferation assay or the
cAMP measurement (i.e., 48 hours after transfection with the siRNA). Cells
transfected with 100 nmol/L scramble or siRNA against p53 were treated 1
day after transfection with 1 Amol/L octreotide for 20 hours and RNA was
extracted to determine Zac1 gene expression. Each transfection with siRNA
was done twice.
Proliferation assays. Cell proliferation was assessed in untreated
cells and in cells treated with 1 Amol/L octreotide or 1 Amol/L leptin for
24 hours using the WST-1 assay (Roche Molecular Biochemicals, Mannheim,
Germany) as previously described (30).
cAMP RIA. Radioimmunologic cAMP determination was done with a
commercial RIA kit from NEN Life Science Products, Inc. (Boston, MA) after
1 Amol/L octreotide treatment. Forskolin (5 mmol/L) was used as a positive
control. The phosphodiesterase inhibitor IBMX (5 mmol/L) was added to all
stimulation solutions. The supernatants were collected and assayed after 4
hours of incubation as previously described (31).
Statistical analysis. Differences were assessed by one-way ANOVA in
combination with Scheffé’s test. P < 0.05 was considered as significant.
Results
Octreotide induces the Zac1 gene. The somatostatin analogue
octreotide increased Zac1 gene expression at concentrations
of 1 and 100 nmol/L (Fig. 1A) after 6 to 24 hours (Fig. 1B). This
induction pattern is in accordance to the cell cycle kinetics
previously described after octreotide treatment in which GH3 cells
accumulated in G0-G1 after 24 hours but there was no effect on cell
cycle and number after 48 hours (2).
Knocking down Zac1 by RNA interference abolished the
antiproliferative effect of octreotide. To examine the role of
Zac1 in the antiproliferative signaling of octreotide, we knocked
down Zac1 using siRNA. siRNA against Zac1 increased cell
proliferation, similar to what was reported in a previous study
using antisense oligonucleotides (Fig. 2A ; ref. 32). Although
24-hour octreotide treatment decreased cell viability in untrans-
fected GH3 cells and in cells transfected with control siRNA
(scramble), it had no effect in cells transfected with 50 and 100
nmol/L siRNA against Zac1 (Fig. 2B). On the other hand,
octreotide decreased cAMP in untransfected and transfected
cells, indicating that the inability of octreotide to decrease cell
proliferation in siRNA-transfected cells is not due to a dysfunc-
tional receptor (Fig. 2C). Furthermore, treatment with leptin,
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which does not affect Zac1 expression,5 decreased cell prolifer-
ation in untransfected cells, as well as in scramble- and siRNA-
transfected cells, as previously documented (data not shown;
ref. 33), further showing that the effect of Zac1 knockdown is
specific for octreotide.
The effect of octreotide on Zac1 gene expression is pertussis
toxin sensitive. Preincubation with 100 ng/mL pertussis toxin for
12 hours abolished the stimulatory effect of octreotide on Zac1
transcription, indicating the involvement of Gi (Fig. 3A). When
activated, Gi generates a-subunits and free hg dimers. Transfecting
GH3 cells with the Ghg sequester h-ARK-CT did not influence the
effect of octreotide on Zac1 expression, indicating the involvement
of the a-subunit but not of hg (Fig. 3B).
A PTP mediates the stimulatory effect of octreotide on Zac1
gene expression. The PTP inhibitor orthovanadate reversed the
effect of octreotide on Zac1 (Fig. 3C). Both SHP-1 and SHP-2 were
expressed in GH3 cells (data not shown). Cells transfected with
dominant negative SHP-1 did not respond to octreotide by
increasing Zac1 expression whereas transfection with the domi-
nant negative SHP-2 had no effect (Fig. 3D), indicating that in
pituitary cells SHP-1 is required for the action of octreotide.
Octreotide inhibits the PI3K/Akt pathway. We examined
which pathways link octreotide to Zac1, downstream of SHP-1. The
MAPK inhibitor PD098059 had no effect on basal or octreotide-
stimulated Zac1 levels (data not shown). On the other hand,
cells treated with the PI3K inhibitors wortmannin and LY294002
displayed increased Zac1 gene expression (Fig. 4A), indicating
that Zac1 is controlled by PI3K and that octreotide may regulate
Zac1 expression by inhibiting its signaling. Octreotide had no effect
on total PDK1 and Akt protein levels but it decreased PDK1 and
Akt phosphorylation (Fig. 4B). These effects were pertussis toxin
sensitive but were not abolished in cells transfected with h-ARK-
CT, indicating involvement of the Gi a-subunit but not of the hg
dimers (data not shown).
Figure 2. A, effect of Zac1 RNA interference on Zac1 mRNA levels in GH3 cell
lysates harvested at the same time with the proliferation assay; cell proliferation
was determined in untreated cells transfected with scramble, 25, 50, and 100
nmol/L Zac1 siRNA. Percentage of untransfected (no siRNA ) cells. *, P < 0.05.
B, cell proliferation was determined after 24-hour treatment with 1 Amol/L
octreotide. Percentage of each control. *, P < 0.05. C, intracellular cAMP release
was determined after 4-hour treatment with 1 Amol/L octreotide. Percentage of
each control. *, P < 0.05. Representative of two independent transfection
experiments.
Figure 1. Zac1 expression as determined by RT-PCR after treatment with
1 Amol/L, 100 nmol/L, 10 nmol/L, and 1 nmol/L octreotide for 24 hours (A) and
with 1 Amol/L octreotide for 5 minutes, 15 minutes, 1, 6, 12, and 24 hours (B ).
Each experiment was done thrice.
5 M. Theodoropoulou, unpublished data.
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The PI3K pathway is switched off by the lipid phosphatase and
tumor suppressor PTEN. However, octreotide did not affect total or
phosphorylated PTEN levels (Fig. 4B), suggesting that its inhibitory
effect on PDK1/Akt is not due to PTEN activation. PI3K was also
shown to be inactivated by SHP-1, which acts by dephosphorylating
the PI3K regulatory subunit p85 (27). In GH3 cells, p85 coimmuno-
precipitated with SHP-1, confirming the physical association
between SHP-1 and p85 (Fig. 4C ; ref. 34). Octreotide decreased the
levels of p85 detected with the 4G10 phosphotyrosine antibody
(Fig. 4C), but had no effect on p85 phosphorylation in cells
transfected with SHP-1dn (Fig. 4D), indicating an important role for
SHP-1 in octreotide signaling. Therefore, it is possible that octreotide
treatment decreases the phosphorylation levels of the PI3K
regulatory subunit p85 and subsequently those of PDK1 and Akt.
Octreotide dephosphorylates and therefore activates
GSK3B. PDK1 and Akt transduce their signals by phosphorylating
and activating or inactivating a number of substrates. Octreotide
decreased p70/S6K, FKHR, and GSK3h phosphorylation levels
without affecting their total protein levels (Fig. 5A). Blocking GSK3h
with 14 Amol/L SB-415286 or 20 mmol/L lithium abolished the
stimulatory effect of octreotide on Zac1, indicating that Zac1
Figure 4. A, Zac1 expression after 24-hour treatment with 1 Amol/L
LY-249002 and 1 Amol/L and 1 nmol/L wortmannin, as determined by
RT-PCR. Each experiment was done thrice. Western blot for Akt-Ser473
shows the efficiency of the inhibitors. B, GH3 cell lysates treated with
1 Amol/L octreotide for 1, 3, and 6 hours analyzed by Western blot using
anti-Akt, anti-pAkt-Ser473, anti-PDK1, anti-pPDK1-Ser241, anti-PTEN, or
anti-pPTEN-Ser380. Representative of three experiments. C, GH3 cell lysates
were immunoprecipitated with Protein A Sepharose and anti-PI3K-p85 or
a control mouse IgG. The immunoprecipitated fractions and the whole-cell
lysates were analyzed by Western blot using anti-phosphotyrosine 4G10,
anti-p85, and anti-SHP-1. Representative of two experiments. D,
untransfected and SHP-1dn-transfected GH3 cell lysates, treated for
10 minutes with 1 Amol/L octreotide, were immunoprecipitated with
Protein A Sepharose and anti-p85, and the immunoprecipitated fractions
were analyzed by Western blot using anti-phosphotyrosine 4G10 and p85.
Representative of two experiments.
Figure 3. Zac1 expression after 20-hour treatment with 1 Amol/L octreotide,
after 16-hour pretreatment with 100 ng/mL pertussis toxin (A), and with 1 Amol/L
octreotide in cells transfected with the hg sequester h-ARK-CT (B). h-ARK-CT
incorporation is proved by the decrease in Ca2+ oscillation in basal and
carbachol-treated GH3 cells. Each determination was done twice. RFU, relative
fluorescence units. *, P < 0.05. C, effect of 2-hour pretreatment with 1 Amol/L,
100 nmol/L, and 10 nmol/L of the PTP inhibitor orthovanadate on the induced
Zac1 expression of octreotide. D, effect of 1 Amol/L octreotide on Zac1 gene
expression in untransfected GH3 cells (control ) and in cells transfected with a
dominant negative vector for SHP-1 (SHP-1dn ) or SHP-2 (SHP-2dn ). SHP-1dn
and SHP-2dn incorporation is shown by Western blot for hemagglutinin (HA ) and
c-myc, respectively. Similar results were shown by two other experiments. All
treatments were done in serum-free DMEM. A and B, quantitative analysis of the
AZAC/AGAPDH ratio for each sample.
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up-regulation happens downstream to GSK3h (Fig. 5B). Octreotide
had no effect on p53 expression, which is one of the GSK3 targets
(data not shown), but it increased p53 transcriptional activity, and this
effectwas pertussis toxin sensitive andwas reversed after cotreatment
with SB-415286 or lithium (Fig. 5C). Knocking down p53 decreased
Zac1 levels and abolished the effect of octreotide on Zac1 transcrip-
tion (Fig. 5D). Therefore, octreotide, by blocking GSK3h phospho-
rylation, activates p53 and increases Zac1 gene expression (Fig. 6).
Discussion
In the present study, it is shown that octreotide increases the
expression of the tumor suppressor gene Zac1 in a pertussis toxin–
sensitive mechanism involving the PTP SHP-1. The role of this
tumor suppressor gene in the antiproliferative action of octreotide
is shown by the fact that cells in which Zac1 was knocked down
failed to respond to the drug treatment. Therefore, Zac1 up-
regulation is necessary for octreotide to exert its growth inhibiting
action. The antiproliferative role of Zac1 is indicated by the fact
that it induces cell cycle arrest and apoptosis (35) and that loss of
Zac1 leads to increased pituitary cell growth (32). The role of ZAC
as a tumor suppressor is further stressed by the observation that
although highly expressed in normal adenohypophysis, it is down-
regulated in most pituitary adenomas (25, 32). Furthermore, Zac1
is lost in transformed rat epithelial ovarian cells (36) and down-
regulated by the EGF mitogenic signaling (37).
Herein, it is also shown that Zac1 is a downstream target
of the PI3K survival pathway. PI3K and its downstream targets
mediate the growth-promoting and cell survival actions of growth
factors, cytokines, and GPCR ligands. On activation, class I PI3Ks
phosphorylate phosphatidylinositol-4,5-biphosphates to phospha-
tidylinositol-3,4,5-triphosphates. Phosphatidylinositol-3,4,5-triphos-
phate recruits Akt to the plasma membrane and changes its
conformation to facilitate its phosphorylation by PDK1 (reviewed
in ref. 38). Octreotide treatment in pituitary cells inhibited both
PDK1 and Akt phosphorylation.
PI3K activity can be inhibited by the lipid phosphatase and tumor
suppressor PTEN. However, we show that octreotide does not affect
PTEN, indicating that its inhibitory action on the PI3K pathway is
not through PTEN. Still, PI3K activity is under tight regulation by
mechanisms controlling its phosphorylation. Class I PI3Ks are
Figure 6. Proposed scheme for the signaling cascade taking place after
octreotide treatment in pituitary cells. Because GH3 cells express only SSTR1
and SSTR2 (53) and octreotide can bind to SSTR2, SSTR3, and SSTR5, but not
to SSTR1 (1), we assume that this pathway originates from the activated SSTR2.
Gia associates with SSTR2 and SHP-1 (15). After 10-minute octreotide
treatment, SHP-1 dephosphorylates the PI3K regulatory subunit p85 and
probably inactivates PI3K without involving PTEN. Three hours later, PDK1,
Akt, and GSK3h are dephosphorylated and GSK3h is activated. This activation
results in an increase in p53 transcriptional activity and Zac1 transcription
6 hours after octreotide treatment. In contrast to a previous model (54), Ghg
and SHP-2 were not needed for the action of octreotide in pituitary cells.
Figure 5. A, GH3 cell lysates treated with 1 Amol/L octreotide for 1, 3, and
6 hours analyzed by Western blot using anti-p70/S6K, anti-p70/S6K-Ser371,
anti-FKHR, anti-pFKHR-Ser380, anti-GSK3h, and anti-pGSK3h-Ser9.
Representative of three experiments. B, Zac1 expression after 24-hour treatment
with 1 Amol/L octreotide alone, octreotide plus 14 Amol/L SB-415286 (SB ) or
20 mmol/L lithium (LiCl ), and SB-415286 or lithium alone. Each experiment was
done thrice. C, effect of 6-hour treatment with 1 Amol/L octreotide alone after
16 hours of pretreatment with 100 ng/mL pertussis toxin, 14 Amol/L SB-415286,
or 20 mmol/L lithium on p53-mediated transcription in GH3 cells transfected with
p53-Luc. RLA, relative luciferase activity. Results are shown as p53-RLA/GFP
ratio. Each experiment was repeated twice. All treatments were done in
serum-free DMEM. D, effect of p53 RNA interference on Zac1 and p53 mRNA
levels in untreated GH3 cells and in cells treated with 1 Amol/L octreotide.
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heterodimers consisting of a regulatory subunit (p85 and p101) and a
catalytic subunit (p110a, h, g, and y). Under resting conditions, p85
stabilizes p110a and inhibits its kinase activity (39) whereas, on
tyrosine phosphorylation, p85 releases its inhibitory action on
p110a, leading to PI3K activation. The PTP SHP-1 was described to
inhibit PI3K by dephosphorylating p85 (27). In accordance to what
was reported before, in pituitary cells, SHP-1 was found to physically
associate with p85, implying that because octreotide can activate
SHP-1, it may also control PI3K. Indeed, in this study, it is shown that
octreotide decreases p85 tyrosine phosphorylation and that SHP-1
plays an important role in this process. Therefore, we speculate that
octreotide initiates its antiproliferative signaling by dephosphor-
ylating p85, through SHP-1, and subsequently decreasing the
phosphorylation levels of members of the PI3K pathway (Fig. 6).
An interesting observation is the time lapse between the
dependent p85 and Akt dephosphorylation of octreotide. Al-
though there is an increasing amount of information about Akt
activation, very little is known about the mechanisms governing
Akt inactivation (40). There is evidence that Akt resides in lipid
rafts where it can remain constitutively active (41, 42). Akt
trapped in a constitutively active form could explain the time
lapse noticed in the present study, but this is a speculation which
remains to be examined.
GPCR activates PI3Kh and PI3Kg, but not PI3Ka, through Ghg,
and this association is always stimulatory (43, 44). Furthermore, Gi
coupled receptors activate PI3Kh also through Ghg (45). In the case
of somatostatin, SSTR1 and SSTR2 were shown to activate PI3K
signaling in a mechanism involving Ghg and SHP-2 (20–22).
However, in the present study, the effect of octreotide is most
probably Ghg independent because sequestering the hg subunits
with h-ARK-CT did not abolish its effect on Akt phosphorylation.
These data suggest that Gi-linked GPCR can interactwith and inhibit
PI3K through the Gi a-subunit, revealing a novel way by which
GPCR, in general, and SSTRs, in particular, can restrict cell growth.
Akt mediates the antiapoptotic and cell survival effects of
growth factors by phosphorylating and subsequently inhibiting
FKHR and GSK-3 (46–48). The inhibitory action of octreotide on
PDK1 and Akt resulted, as expected, in decreased FKHR and
GSK3h phosphorylation levels. GSK3h inhibition abolished the
stimulatory effect of octreotide on Zac1 gene expression, indicating
that this tumor suppressor gene is downstream to GSK3h. GSK3h
regulates cell cycle progression by affecting cyclin E and cyclin D1
proteolysis and subcellular localization, members of the Forkhead
family of transcription factors, the tumor suppressor tuberin
(TSC2), and p27/Kip1 (reviewed in refs. 48, 49). Furthermore,
GSK3h phosphorylates p53 and activates its transcriptional activity
(50). Because p53 activates Zac1 transcription (51), it is possible
that the effect of octreotide on Zac1 is due to up-regulation of p53
transcriptional activity. Indeed, knocking down p53 abolished the
stimulatory effect of octreotide on Zac1 transcription.
The present study suggests a novel mechanism of octreotide
action through direct inhibition of components of the PI3K pathway.
This observation contrasts with previous studies in pancreatic
tumor cells, in which octreotide did not affect basal, but it inhibited
growth factor–induced Akt phosphorylation (23, 52), indicating that
octreotide signaling can vary among different cell types. Octreotide
signaling as described herein initiates by inhibiting the phosphor-
ylation of the PI3K regulatory subunit p85 through the Gi a-subunit
and SHP-1. Inhibition of the PI3K pathway leads to GSK3h
activation, increased p53 transcriptional activity, and subsequently
Zac1 up-regulation. Zac1 regulates cell growth and its presence is
required for octreotide to stop cell cycle progression, because cells in
which Zac1 is knocked down cannot respond to the antiproliferative
action of this somatostatin analogue.
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